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L
ung cancer is the leading 
cause of cancer death in 
many countries. To date, 
chemotherapy with cytotoxic agents 
has been the mainstay of treatment for 
advanced lung cancer. However, the 
activity of these agents is quite limited, 
and they have severe adverse effects. 
Recent, rapid advances in molecular 
biology have led to the development 
of many new agents that inhibit the 
activities of speciﬁ  c molecules related 
to tumor growth, invasion, or metastasis 
[1], and these agents have the potential 
to improve the outcome of lung 
cancer treatment. But we have not yet 
managed to successfully deliver these 
agents from the bench to the bedside.
Molecular Therapy for Lung Cancer
Geﬁ  tinib is the ﬁ  rst “molecular-target 
agent” for lung cancer that inhibits 
the tyrosine kinase of the epidermal 
growth factor receptor (EGFR; also 
known as ERBB1). EGFR is frequently 
overexpressed in non-small-cell 
lung cancer (NSCLC), especially in 
squamous cell carcinoma, and its 
expression is related to the cancer’s 
proliferation. Initial clinical trials of 
geﬁ  tinib showed its modest clinical 
activity in patients who had failed 
previous standard chemotherapy. 
But subsequent randomized trials in 
patients with previously untreated, 
advanced NSCLC have not shown 
a clinical advantage of geﬁ  tinib 
combined with standard chemotherapy 
over chemotherapy alone [2,3,4,5]. 
Erlotinib, another EGFR tyrosine 
kinase inhibitor for treating NSCLC, 
which was approved by the United 
States Food and Drug Administration 
in November 2004, has a therapeutic 
proﬁ  le similar to that of geﬁ  tinib. 
Erlotinib has shown a survival beneﬁ  t 
in a phase III trial for chemo-refractory 
NSCLC that compared erlotinib to 
best supportive care [6]. (To date, 
there have been no trials showing a 
survival beneﬁ  t of EGFR inhibitors over 
standard chemotherapy.) Interestingly, 
in these trials of EGFR inhibitors, 
EGFR expression levels in the tumors 
were not correlated with the response; 
high response rates were seen in 
women, patients with adenocarcinoma, 
nonsmokers, and Japanese patients. 
Recent studies have now shed light on 
why certain patients are more likely to 
respond than others—the key lies in 
the presence of gene mutations.
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EGFR Gene Mutations in NSCLC
In April and May 2004, two new 
studies published in Science and 
the New England Journal of Medicine 
helped to explain at the molecular 
level the low clinical activity of 
EGFR inhibitors [7,8]. These studies 
identiﬁ  ed somatic mutations in the 
EGFR gene, especially around the 
region encoding the ATP-binding 
pocket of the receptor’s tyrosine kinase 
domain. These mutations increased the 
sensitivity of tumor cells to geﬁ  tinib. 
A high incidence of mutations was 
detected in patients with NSCLC 
that had a durable clinical response 
to geﬁ  tinib, and subsequent studies 
revealed that these mutations were also 
related to the response to erlotinib. 
Moreover, such mutations were 
more frequently detected in patients 
with adenocarcinoma, in women, in 
Japanese patients, and in nonsmokers 
[9]—results that were compatible with 
previous clinical data. 
These ﬁ  ndings should hopefully 
lead to the identiﬁ  cation of subgroups 
of patients who are likely to beneﬁ  t 
substantially from such EGFR 
inhibitors. But another question was 
raised by these studies: is it only EGFR 
gene mutations that determine the 
response to EGFR inhibitors?
RAS Gene Mutations in NSCLC
The RAS proteins are low-molecular-
weight GTPases that are bound to the 
inner side of the cell membrane. They 
are involved in signal transduction 
pathways: they regulate downstream 
effector proteins such as Raf/MAP 
kinase and PI3 kinase, under the 
inﬂ  uence of various cell surface 
receptors including EGFR (Figure 
1). Mutations of the K-ras gene have 
been found in up to 30% of lung 
adenocarcinomas and have been 
considered a poor prognostic factor 
[10]. A study by Pao and colleagues 
published in this issue of PLoS Medicine 
suggests that the K-ras mutation is 
an important predictive factor in 
deﬁ  ning which patients will beneﬁ  t 
from receiving EGFR inhibitors [11]. 
In Pao and colleagues’ study, the K-ras 
mutations were completely associated 
with a lack of response to EGFR 
inhibitors (0/14 tumors with K-ras 
mutations were sensitive). The EGFR 
mutations were signiﬁ  cantly related to 
response (17/17 tumors with EGFR 
mutations were sensitive), as observed 
in previous studies. 
Although the number of tumors 
examined in this study may be too small 
to lead to a deﬁ  nite conclusion—and, 
furthermore, about half of tumors were 
retrospectively collected—this study 
is the ﬁ  rst to show that mutations of 
EGFR and K-ras are not related and 
that K-ras mutations are associated with 
a lack of sensitivity to EGFR inhibitors. 
However, since the sensitivity of the 
method for ﬁ  nding each mutation 
inﬂ  uences how often it is detected, 
standardization of detection methods 
is important. Hence, the true 
incidence of K-ras mutations in NSCLC 
(including non-adenocarcinoma) and 
their refractoriness to EGFR inhibitors 
need to be established in further 
studies. In fact, the reported incidence 
of EGFR mutations differs between 
institutions. In addition, although Pao 
and colleagues’ study examined such 
mutations only by DNA sequence, 
mRNA or protein expression would 
show mutation status more accurately.
Therapeutic Implications
In the clinical setting, prolonged 
disease stabilization with no measurable 
reduction in tumor size is seen in about 
half of patients treated with EGFR 
inhibitors, and a signiﬁ  cant survival 
beneﬁ  t in this group was shown in a 
phase III trial [6]. The mutation status 
of the EGFR gene and K-ras gene 
among those stabilized tumors should 
be evaluated; it may reveal two different 
groups differentiated by mutation 
status.
It will also be important to establish 
whether, in tumors with an EGFR 
mutation that eventually acquire 
resistance to EGFR inhibitors, the 
resistance is associated with a change 
of EGFR status (mutation or change 
in expression) or is associated with a 
change of K-ras status. Such changes 
can be revealed by re-examination 
of tumors at the time of relapse. If 
resistance is K-ras dependent, the 
new “K-ras inhibitors” (unfortunately 
not yet available) may be of help for 
patients who have developed a K-ras 
mutation, as well as for patients whose 
tumors harbor K-ras mutations from 
the beginning.
Although many issues still need 
to be resolved step by step through 
prospective trials to show the beneﬁ  t 
of this new strategy, these mutations 
are promising predictive factors for 
the success of EGFR inhibitors. Even if 
the population who may beneﬁ  t from 
EGFR inhibitors (such as patients who 
are positive for an EGFR mutation and 
negative for a K-ras mutation) is very 
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Figure 1. EGFR Signal Transduction in Cancer Cells
Arrows indicate stimulation, and T-bars, inhibition. EGFR-I, EGFR inhibitor; MEK, 
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small, the response rate of over 80% 
is encouraging, and has never before 
been achieved in advanced NSCLC. 
Finally, it is important to detect which 
patients derive no beneﬁ  t from EGFR 
inhibitors because severe adverse 
effects such as acute lung injury can 
occur in any patient treated with these 
drugs [12]. By combining all the factors 
that relate to response or resistance, 
patients who will beneﬁ  t from 
treatment can hopefully be identiﬁ  ed. 
Undoubtedly we have taken a great step 
forward in molecular therapy for lung 
cancer treatment.  
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